Lauren Biscaldi

Half of the study participants were randomly prescribed oral vitamin D3 and continued their prescribed metformin for 6 months; the remainder received metformin only.

A meta-analysis did not demonstrate a benefit of beta-blockers in reducing major adverse cardiovascular events in a population of patients with stable coronary artery disease without previous history of myocardial infarction or left ventricular dysfunction.

This first report on the safety of selective intracoronary hypothermia is a novel therapy that may reduce myocardial reperfusion injury in STEMI that has had demonstrated efficacy in animal model studies.

This study examined outcomes in patients with ischemic vs nonischemic cardiomyopathy who are treated with ICD therapy for the primary prevention of sudden cardiac death.

Investigators sought to find out whether short-term use of liraglutide had a cardioprotective effect in people with type 2 diabetes.

DAPT de-escalation was ranked as the most effective strategy for preventing all-cause and cardiovascular death in patients with acute coronary syndrome.

The goal of this study was to determine the relationship between subclinical coronary artery disease and the severity of nonalcoholic fatty liver disease.

Researchers weighed the risks and benefits of traditional heart failure therapies in low-risk patients with transthyretin cardiac amyloidosis.

The objective of this study was to test the efficacy and safety of revacept, a novel, lesion-directed antithrombotic drug, acting as a competitive antagonist to platelet glycoprotein VI.

This study challenges the view that history of cardiovascular disease is a key factor in decisions about blood pressure-lowering treatment.